Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Loading
Start 30 days free, no card. Full Pro access for a month, then decide. Start free
Industry-level sentiment and macro signals, built from public earnings calls. Part of the Healthcare sector.
Showing calendar 2026 Q2Free· the newest quarter (2026 Q3) is Pro.
Industry Sentiment Index · Calendar 2026 Q2
As of 2026 Q2, the Tellvest aggregate earnings-call sentiment for the Large Pharmaceutical Companies industry is 7.4/10 across 9 companies.
2024 Q4–2026 Q2. Each earlier point averages the available scores of this quarter’s 9-company panel in that quarter; companies without a score in an earlier quarter don’t contribute, so the number behind each point can vary.
Earnings-call analysis · calendar 2026 Q2
What management and analysts said on calls mapped to this calendar quarter.
The industry's average sentiment score rose from 6.56 to 7.44 in a quarter when three of the nine companies reported losses on deal or impairment charges. Gilead Sciences (GILD) took $11.2 billion of acquired IPR&D expense, Merck (MRK) took a $5.7 billion charge for the Terns Pharmaceuticals acquisition, and Pfizer (PFE) booked a $4.3 billion noncash impairment. All three still raised full-year revenue or sales guidance and each earned a positive guidance adjustment, so the one-time charges did not drag their scores.
Market context
Public price data. It covers the trailing year to the latest close, not calendar 2026 Q2.
Method
A composite score derived from averaging overall earnings sentiment across all analyzed companies in this industry for the selected calendar quarter. Score is 0–10 (10 = most positive).
| Signal | Companies | Direction breakdown |
|---|---|---|
| Regulation Policy | 7 | 2122 |
| FX | 5 | 1112 |
| Consumer Demand | 3 | 111 |
% change over the trailing year, log scale. 1Y and YTD are each name’s own price return. Equal-weight: average of every full-history member, weighted equally, not rebalanced.